Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
Silvia Novello(University of Turin), Giorgio V. Scagliotti(University of Turin), Rafael Rosell(Institut Català d'Ornitologia), Mark A. Socinski(University of North Carolina at Chapel Hill), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center), J. Atkins(Southeastern Medical Oncology Center), Cinta Pallarés, R Burgess, L. Tye(Pfizer (United States)), Paulina Selaru(Pfizer (United States)), Edward Wang(Pfizer (United States)), Richard C. Chao(Pfizer (United States)), Ramaswamy Govindan(Washington University in St. Louis)
Cited by 0Open Access
Abstract
Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
Related Papers
Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
Brian I. Rini, Ila Tamaskar, Phillip Shaheen et al.|JNCI Journal of the National Cancer Institute|2007|376